
Opinion|Videos|February 27, 2025
Initial Treatment Options for Liver-Confined Unresectable HCC
Author(s)Amit Singal, MD
The panelist discusses first-line options including atezolizumab plus bevacizumab, lenvatinib, and sorafenib. Second-line treatments include regorafenib, cabozantinib, and ramucirumab. Clinical trials should be prioritized when available.
Advertisement
Video content above is prompted by the following:
- Please briefly review the treatment options for patients with hepatocellular carcinoma (HCC) confined to the liver but unresectable according to NCCN guidelines.
- Please discuss standard treatment modalities and share your impressions on the initial treatment approach in this case.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
3
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
4
FDA Oncology Update January 2026: New Horizons in Precision Medicine
5



















